加载中...

MedXY News - obesity

MedXY AI/MedXY News/Tag: obesity

MedXY News

EnglishTag

obesity

98 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis

Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis

A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk

Section: Critical CareDec 31, 2025

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting

Section: Cardiology

Dec 29, 2025

Norepinephrine at Extubation: Challenging the Hemodynamic Safety Paradigm in Critically Ill Patients with Obesity

Norepinephrine at Extubation: Challenging the Hemodynamic Safety Paradigm in Critically Ill Patients with Obesity

A multicenter validation study confirms that low-dose norepinephrine at the time of extubation does not increase reintubation rates in patients with obesity, offering clinicians greater flexibility in weaning strategies for hemodynamically

Section: AnesthesiologyDec 28, 2025

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig

Section: CardiologyDec 26, 2025

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI

Section: CardiologyDec 26, 2025

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesit

Section: CardiologyDec 24, 2025

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Section: CardiologyDec 23, 2025

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus

Section: CardiologyDec 5, 2025

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gas

Section: Diabetes & EndocrinologyNov 28, 2025

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression

Section: newsNov 23, 2025

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.

Section: newsNov 23, 2025

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids

Adenotonsillectomy Lowers Blood Pressure Percentiles in Children With Mild OSA — Greatest Benefit in Overweight Kids

An exploratory analysis of the PATS randomized trial found early adenotonsillectomy reduced 12‑month systolic and diastolic BP percentiles versus watchful waiting in children with mild obstructive sleep‑disordered breathing, with larger DBP

Section: CardiologyNov 21, 2025

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promisi

Section: Diabetes & EndocrinologyNov 14, 2025

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

Section: CardiologyNov 11, 2025

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2

Section: Critical CareNov 7, 2025

Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits

Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits

A multi-cohort human study with mouse and Drosophila validation implicates gut microbes and the tryptophan metabolite 3‑hydroxyanthranilic acid in modulating attention in obesity, suggesting microbiota-directed interventions could improve c

Section: GastroenterologyNov 7, 2025

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium

In a large prospective cohort, obese BMI (≥30) was associated with worse post-concussion neurocognitive outcomes and a persistently proinflammatory blood biomarker profile, despite fewer baseline symptoms. Findings suggest obesity modifies

Section: Diabetes & EndocrinologyNov 5, 2025

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

Section: Diabetes & EndocrinologyNov 1, 2025

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

New evidence from the UK Biobank reveals that clinical obesity, defined by obesity-related dysfunctions, significantly elevates all-cause mortality risk. Early detection and intervention are key to reducing mortality associated with both pr

Section: Diabetes & EndocrinologyOct 29, 2025

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt

Section: Diabetes & EndocrinologyOct 29, 2025

Prev 1 2 3 4 5 Next